Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials

被引:7
作者
Wen, Jimmy [1 ]
Syed, Burhaan [1 ]
Leapart, Jared [1 ]
Shehabat, Mouhamad [1 ]
Ansari, Ubaid [1 ]
Akhtar, Muzammil [1 ]
Razick, Daniel [1 ]
Pai, David [1 ]
机构
[1] Calif Northstate Univ, Coll Med, Elk Grove, CA 95757 USA
关键词
adverse effects; body composition; performance; SARMs; selective androgen receptor modulators; DOUBLE-BLIND; SAFETY; MEN; PHARMACOKINETICS; ENOBOSARM; THERAPY;
D O I
10.1111/cen.15135
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Selective androgen receptor modulators (SARMs) are potential treatments for ameliorating age-related physicaldysfunctions caused by sarcopenia, cachexia and chronic illnesses such as cancer. The purpose of this systematic review is toanalyse the effect of SARMs on physical performance and body and evaluate their safety profile. Methods: A systematic review search criteria following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed in three databases for studies reporting physical parameter outcomes after SARMintervention. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, meanfollow-up time, pre and post-intervention outcomes and rates of complications. Results: Nine studies, including 970 patients with a mean age of 57.1 years (35.3-75.9) and a mean follow-up of 80 days(14-180), were included. Six SARMs were analysed: LGD-4033, PF-06260414, GSK2881078, GTx-024, MK-0773 and OPK-88004.Mean pre-intervention stair climbing power (five studies), one repetition maximum leg press (four studies) and short physicalperformance battery (SPPB) score (two studies), lean body mass (seven studies) and fat mass (five studies) were 352.24 W(69.79-678.7), 1822.77 N (1176.8-2407.3), 9.15 (7.95-9.9), 49.46 kg (30.94-63.9) and 21.99 kg (13.3-33), respectively. Meanpost-intervention values were 315.16 W (89.46-525.73 W), 2191.27 N (1375.87-2462.9 N), 9.79 (8.88-10.4), 50.86 kg(31.02-67.29) and 21.85 kg (12.54-32.16), respectively. Conclusion: SARMs have a positive effect on physical performance and body composition and are associated with moderaterates of mild to moderate adverse effects (AEs) and a low rate of severe AEs.
引用
收藏
页码:3 / 27
页数:25
相关论文
共 39 条
[1]   The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men [J].
Basaria, Shehzad ;
Collins, Lauren ;
Dillon, E. Lichar ;
Orwoll, Katie ;
Storer, Thomas W. ;
Miciek, Renee ;
Ulloor, Jagadish ;
Zhang, Anqi ;
Eder, Richard ;
Zientek, Heather ;
Gordon, Gilad ;
Kazmi, Syed ;
Sheffied-Moore, Melinda ;
Bhasin, Shalender .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2013, 68 (01) :87-95
[2]   Selective androgen receptor modulators as function promoting therapies [J].
Bhasin, Shalender ;
Jasuja, Ravi .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2009, 12 (03) :232-240
[3]   Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects [J].
Bhattacharya, Indranil ;
Tarabar, Sanela ;
Liang, Yali ;
Pradhan, Vivek ;
Owens, Jane ;
Oemar, Barry .
CLINICAL THERAPEUTICS, 2016, 38 (06) :1401-1416
[4]   Selective androgen receptor modulators: the future of androgen therapy? [J].
Christiansen, Andrew R. ;
Lipshultz, Larry I. ;
Hotaling, James M. ;
Pastuszak, Alexander W. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 :S135-S148
[5]   Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women [J].
Clark, Richard V. ;
Walker, Ann C. ;
Andrews, Susan ;
Turnbull, Philip ;
Wald, Jeffrey A. ;
Magee, Mindy H. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (10) :2179-2194
[6]   The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial [J].
Dalton, James T. ;
Barnette, Kester G. ;
Bohl, Casey E. ;
Hancock, Michael L. ;
Rodriguez, Domingo ;
Dodson, Shontelle T. ;
Morton, Ronald A. ;
Steiner, Mitchell S. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (03) :153-161
[7]   Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial [J].
Dobs, Adrian S. ;
Boccia, Ralph V. ;
Croot, Christopher C. ;
Gabrail, Nashat Y. ;
Dalton, James T. ;
Hancock, Michael L. ;
Johnston, Mary A. ;
Steiner, Mitchell S. .
LANCET ONCOLOGY, 2013, 14 (04) :335-345
[8]   Benefits and Risks of Testosterone Treatment in Men with Age-Related Decline in Testosterone [J].
dos Santos, Marcelo Rodrigues ;
Bhasin, Shalender .
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021, 2021, 72 :75-91
[9]   Analysis of the growing public interest in selective androgen receptor modulators [J].
Efimenko, Iakov, V ;
Chertman, Willy ;
Masterson, Thomas A. ;
Dubin, Justin M. ;
Ramasamy, Ranjith .
ANDROLOGIA, 2021, 53 (11)
[10]   Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey [J].
Efimenko, Iakov, V ;
Valancy, David ;
Dubin, Justin M. ;
Ramasamy, Ranjith .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2022, 34 (08) :757-761